Evolva has made a donation to the University of Toronto Faculty of Dentistry in Toronto, Ontario, Canada to support a research initiative aimed at managing periodontitis using resveratrol.
The two-year study is being conducted under the direction of Howard Tenenbaum and Michael Glogauer, professors at the faculty, who are developing strategies for healing and repairing gum tissues caused by periodontitis—using resveratrol.
This study marks the first time that human models are being used to observe the potential health benefits of pure resveratrol in relation to managing or even reversing periodontitis.
The conclusion from numerous studies and the World Health Organisation is that periodontitis is one of the world’s most common diseases.
The World Health Organisation in 2012 says the most severe form of the disease affects an estimated 15-20% of all middle-aged adults (35-44 years old).
Periodontitis can range from simple gum inflammation to a more serious disease state that results in major damage to the soft tissue and bone that support the teeth. Periodontitis is an ‘osteoimmune’ condition similar to arthritis.
In the worst cases of periodontitis, patients lose bone and previously healthy teeth.
An August 2015 study in The Journal of Dental Research estimated that as much as US$54 billion is spent each year globally in an attempt to tackle periodontitis.